Drug Profile
Research programme: acetyl CoA carboxylase 1/2 allosteric inhibitors - Gilead Sciences
Alternative Names: ND-630; ND-646; ND-654Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Nimbus Discovery
- Developer Gilead Sciences; Nimbus Therapeutics
- Class Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Diabetes mellitus; Liver cancer; Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Non-small cell lung cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA
- 28 May 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
- 28 May 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA